A nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoid carcinoma model compared to dacarbazine suspension

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 3, 2011, Pages 277-283

  Kakumanu, Srikanth ^a   Tagne, Jean Bosco ^a   Wilson, Thomas A ^a   Nicolosi, Robert J ^a  

^a UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

Author keywords

Dacarbazine; Epidermoid carcinoma; Nanoemulsion; Xenograft mouse model

Indexed keywords

ANTICANCER DRUG; DACARBAZINE; EPIDERMOID CARCINOMA; INTRAMUSCULAR INJECTIONS; MOUSE MODELS; NANOEMULSION; NUDE MICE; POLYDISPERSITY INDICES; TOPICAL APPLICATION; TUMOR SIZE; WATER DISPERSION; XENOGRAFT MOUSE MODEL;

BIOLOGICAL MATERIALS; POLYDISPERSITY; TUMORS; ZETA POTENTIAL;

SUSPENSIONS (FLUIDS);

DACARBAZINE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; DRUG FORMULATION; HUMAN; HUMAN CELL; MOUSE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR XENOGRAFT; ZETA POTENTIAL;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DACARBAZINE; EMULSIONS; HUMANS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; SUSPENSIONS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 79956340886     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2010.12.002     Document Type: Article

References (49)

1. Chen J., Ruczinski I., Jorgensen T.J., Yenokyan G., Yao Y., Alani R., et al. Nonmelanoma skin cancer and risk for subsequent malignancy. Natl Cancer Inst 2008, 100:1215-1222.
2. Hearn R.M.R., Kerr A.C., Rahim K.F., Ferguson J., Dawe R.S. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet phototherapy. Br J Dermatol 2008, 159:931-935.
3. Kennedy C., Bajdik C.D., Willemze R., Bouwes Bavinck J.N. Chemical exposures other than arsenic are probably not important risk factors for squamous cell carcinoma, basal cell carcinoma and malignant melanoma of the skin. Br J Dermatol 2005, 152:194-197.
4. Ramanathan R.K., Cnaan A., Hahn R.G., Carbone P.P., Haller D.G. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001, 12:1139-1143.
5. Meer L., Janzer R.C., Kleihues P., Kolar G.F. In vivo metabolism and reaction with DNA of the cytostatic agent,5-(3,3-dimethyl-1-triazeno)imidazole-4-carboximide (DTIC). Biochem Pharmacol 1986, 35:3243-3247.
6. Madan V., Hoban P., Strange R.C., Fryer A.A., Lear J.T. Genetics and risk factors for basal cell carcinoma. Br J Dermatol 2006, 154:5-7.
7. Ganesh Kumar S., Narayana K., Bairy K.L., Souza Urban J.A., Paul S.V., Gopalakrishna K. Dacarbazine induces genotoxic and cytotoxic germ cell damage with concomitant decrease in testosterone and increase in lactate dehydrogenase concentration in the testis. Mutat Res 2006, 607:240-252.
8. Ancheva M.N., Boeva M.N. The effect of biocarbazine on the indices of humoral and cellular immunity in mice. Eksp Onkol 1990, 12:37-40.
9. Ohshio G., Hosotani R., Imamura M., Sakahara H., Ochi J., Kubota N. Gastrinoma with multiple liver metastases: effectiveness of dacarbazine (DTIC) therapy. J Hepatobiliary Pancreat Surg 1998, 5:339-343.
10. Levy A., Guitera P., Kerob D., Ollivaud L., Archimbaud A., Dubertret L., et al. Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma. Ann Dermatol Venereol 2006, 133:157-160.
11. Jiao J., Rhodes D.G., Burgess D.J. Multiple emulsion stability: pressure balance and interfacial film strength. J Colloid Interface Sci 2002, 250:444-450.
12. Sonneville-Aubrun O., Simonnet J.T., Alloret F.L. Nanoemulsions: a new vehicle for skincare products. Adv Colloid Interface Sci 2004, 108-109:145-149.
13. Sadurni N., Solans C., Azemar N., Celma M.J.G. Studies on the formation of O/W nanoemulsions, by low-energy emulsification methods, suitable for pharmaceutical applications. Eur J Pharm Sci 2005, 26:438-445.
14. Tadros T., Izquierdo P., Esquena J., Solans C. Formation and stability of nanoemulsions. Adv Colloid Interface Sci 2004, 108-109:303-318.
15. Constantinides P.P., Tustian A., Kessler D.R. Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev 2004, 56:243-255.
16. Kumar R., Chen M.H., Parmar V.S., Samuelson L.A., Kumar J., Nicolosi R.J., et al. Supramolecular assemblies based on copolymers of PEG600 and functionalized aromatic diesters for drug delivery applications. J Am Chem Soc 2004, 126:1060-1064.
17. Cavalli R., Peira E., Caputo O., Gasco M.R. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins. Int J Pharm 1999, 182:59-69.
18. Attivi D., Wehrle P., Ubrich N., Damge C., Hoffman M., Maincent P. Formulation of insulin-loaded polymeric nanoparticles using response surface methodology. Drug Dev Ind Pharm 2005, 31:179-189.
19. Merisko-Liversidge E., McGurk S.L., Liversidge G.G. Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn-insulin. Harm Res 2004, 21:1545-1553.
20. Pan Y., Zheng J.M., Zhao H.Y., Li Y.J., Xu H., Wei G. Relationship between drug effects and particle size of insulin-loaded bioadhesive microspheres. Acta Pharmacol Sin 2002, 23:1051-1056.
21. Vila A., Sanchez A., Evora C., Soriano I., McCallion O., Alonso M.J. PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 2005, 292:43-52.
22. Thanos C.G., Liu Z., Reineke J., Edwards E., Mathiowitz E. Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride. Pharm Res 2003, 20:1093-1100.
23. Kuo F., Wilson T.A., Kifle L., Panagiotou T., Gruverman I., Tagne J.B., et al. A nanoemulsion of an anti-oxidant synergy formulation reduces tumor growth rate in neuroblastoma-bearing nude mice. J Exp Ther Oncol 2007, 6:129-135.
24. Kotyla T., Kuo F., Moolchandani V., Wilson T.A., Nicolosi R.J. Increased bioavailability of a transdermal application of a nano-sized emulsion preparation. Int J Pharm 2007, 347:144-148.
25. Kuo F., Subramanian B., Kotyla T., Wilson T.A., Yoganathan S., Nicolosi R.J. Nanoemulsions of an anti-oxidant synergy formulation containing gamma tocopherol have enhanced bioavailability and anti- inflammatory properties. Int J Pharm 2008, 363:206-213.
26. Subramanian B., Kuo F., Ada E., Kotyla T., Wilson T.A., Yoganathan S., et al. Enhancement of anti-inflammatory property of aspirin in mice by a nanoemulsion preparation. Int J Immunopharmacol 2008, 8:1533-1539.
27. Tagne J.B., Kakumanu S., Nicolosi R.J. Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model. Mol Pharm 2008, 5:1055-1063.
28. Tagne J.B., Kakumanu S., Ortiz D., Shea T., Nicolosi R.J. Nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line. Mol Pharm 2008, 5:280-286.
29. Snedecor G.W., Cochran W.G. Statistical methods 1980, The Iowa State University Press, Ames, IA.
30. Torchilin V.P. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 2004, 61:2549-2559.
31. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics; Bioconjugated nanoparticles for drug deliver. Mol Cancer Ther 2006, 5:1909-1917.
32. Jarzyna P.A., Skajaa T., Gianella A., Cormode D.P., Samber D.D., Dickson S.D., et al. Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials 2009, 30:6947-6954.
33. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
34. Desai A., Vyas T., Amiji M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci 2008, 97:2745-2756.
35. Zhao X., Liu J.P., Zhang X., Li Y. Enhancement of transdermal delivery of theophylline using microemulsion vehicle. Int J Pharm 2006, 327:58-64.
36. Shetty B.V., Schowen R.L., Slavik M., Riley C.M. Degradaion of dacarbazine in aqueous solutions. J Pharm Biomed Anal 1992, 10:675-683.
37. Aatmani M.E.I., Poujal S., Astre C., Malosse F., Pinguet F. Stability of dacarbazine in amber glass vials and polyvinyl chloride bags. Am J Health Syst Pharm 2002, 59:1351-1356.
38. Gao D., Xu H., Philbert M.A., Kopelman R. Bioeliminable nanohydrogels for drug delivery. Nano Letters 2008, 8:3320-3324.
39. Higaki K., Asai M., Suyama T., Nakayama K., Ogawara K., Kimura T. Estimation of intradermal disposition kinetics of drugs: II. Factors determining penetration of drugs from viable skin to muscular layer. Int J Pharm 2002, 239:129-141.
40. Jylha E.V., Vuori M.L., Pyykko K., Huupponen R. Plasma concentration of topically applied betaxolol in elderly glaucoma patients. J Ocular Pharm Therap 2001, 17:207-213.
41. Poyhia R., Vainio A. Topically administered ketamine reduces capsaicin-evoked mechanical hyperalgesia. Clin J Pain 2006, 22:32-36.
42. Sauer J.M., Smith R.L., Bao J., Kattnig M.J., Kuester R.K., Sipes I.G. Metabolic and dispositional fate of 1,2-dibromo-2,4-dicyanobutane in the male Fischer 344 rat. Drug Metab Dispos 1998, 26:429-436.
43. Koziara J.M., Whisman T.R., Tseng M.T., Mumper R.J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release 2006, 112:312-319.
44. Peng J., Xing X., Wang K., Tan W., He X., Huang S. Influence of anions on the formation and properties of chitosan-DNA nanoparticles. J Nanosci Nanotechnol 2005, 5:713-717.
45. Grosse C., Pedrosa S., Shilov V.N. On the influence of size, zeta potential, and state of motion of dispersed particles on the conductivity of a colloidal suspension. J Colloid Interface Sci 2002, 251:304-310.
46. Matos C., de Castro B., Gameiro P., Lima J.L., Reis S. Zeta-potential measurements as a tool to quantify the effect of charged drugs on the surface potential of egg phosphatidylcholine liposomes. Langmuir 2004, 20:369-377.
47. Lockman P.R., Koziara J.M., Mumper R.J., Allen D.D. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 2004, 12:635-641.
48. Lockman P.R., Mumper R.J., Khan M.A., Allen D.D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002, 28:1-13.
49. Mahato R.I. Water insoluble and soluble lipids for gene delivery. Adv Drug Deliv Rev 2005, 57:699-712.